We know that no two biologics development processes are the same and your needs can change in an instant or gradually over time.
That's why we offer adaptable contract development and manufacturing solutions for biotechs needing to develop and commercialize biologics. We do this by balancing speed, risk and cost through custom solutions, by leveraging our bioprocessing technologies and process development expertise.
Just Got Funding?
|
You Need to Reach Pre-clinical Phase? What Now?Read article |
Just Filed for IND?
|
Because every drug development process is different, we understand that you need an agile partner who intuitively understands your goals and not only mitigates risk, but also shares it with you.
We design process development strategies to deliver the optimal balance between speed to clinic and cost, without ever compromising on quality or patient safety.
Start your journey the right way for you.
Optimize your Biologic’s Analytical Program
|
Read our ebook » |
Video: The main driver of regulations and risk assessment is to ensure patient safety. |
Are you filing for IND?
|
Accelerate delivery of high-producing cell linesFor clients with a very challenging timeline, our mini-pool approach as fast track allows us to use material from mini pools to start process development in parallel with cell line development. |
Read case study » | |
Increase the titer of a difficult to express moleculeOur custom approach delivered the desired increase in productivity, without the need to explore different cell lines or change the molecular construct, and helped position our client to continue development of the molecule. |
Read case study » | |
Key considerations for analytical developmentBecause analytical methods are so integral to your entire workflow, you should start early, at the time of upstream process development. |
Read case study » |
As you drive towards long-term commercial success, our adaptable approach offers the right combination of speed and efficiency through process scale-up.
Whether you have brought a product to market before or you are doing it for the first time, we will complement your experience and provide continued regulatory support to help you achieve long-term success.
As you move beyond the clinical trial phases, we will continue to find the balance between cost and speed so that you can get things right first time.
Reach your long-term goals the way you need to.
Trends in Outsourcing the Development and Manufacturing of BiologicsMany factors must be considered when determining the best approach for development and manufacturing of a biopharmaceutical. The right strategy must align with organizational objectives, accelerate progress toward key milestones within regulatory expectations, and ensure quality and patient safety. In this whitepaper, we share highlights from a global market research survey of small, mid-sized and large biopharmaceutical companies on trends related to outsourcing. |
Read our Whitepaper » |
A Scale-up from 3L directly to 2,000LOnce a robust upstream process established, scalability is critical to support demand for drug substance during clinical development. We developed a strategy to enable a direct, efficient and robust tech transfer of a monoclonal antibody production process from a 3L bioreactor to 2000L without the need for any intermediate volumes. |
Watch webinar now » |
We work with you to support reliable and reproducible tech transfer, no matter when or at what stage of the development process, ensuring the ability to move production between providers freely.
From defining critical quality attributes, to creating a detailed process description, and of course developing a successful transfer protocol, we can help you minimize time and cost spent during tech transfer while always staying in line with regulatory guidelines.
A direct scale-up from 3L to 2,000LOur clients can significantly shorten their scale-up process thanks to our streamlined approach – accelerating the time to market and delivering a competitive advantage. |
Read case study » | |
Optimize the formulation for a monoclonal antibodyFor clients who are on an aggressive timeline and budget, we can deliver an optimized formulation in 3 months. |
Read case study » | |
Reduce the host cell protein from bioreactor harvestOur client had one month to reduce the level of HCPs in the bioreactor harvest prior to a production run to supply drug substance for a scheduled Phase 1 clinical trial. |
Read case study » | |
Key considerations for tech transferAt some point, you will need to transfer a process either to another team for scale-up purposes or perhaps to another building, company or geography for manufacturing. Proactive planning for these events is essential. |
Read best practices » |
Video: A partner for small biotech who want to outsource their molecule development from DNA to market.
We're a small and flexible team, but we're also part of Merck KGaA, Darmstadt, Germany, one of the largest science and technology companies in the world. We bring a wealth of in-house expertise that helps biotech companies take their drug candidates from bench to bedside.
We provide bioprocessing solutions, combining technology and deep development expertise, giving our clients the agility to reach commercial success on their terms.
33+
Years in
process development |
250+
Biologics
(Antibodies, hormones,
fc-fusions, recombinant proteins) |
75+
GMP Drug
Substance Batches Released since 2012
|
Our experts are always looking for innovative ways to optimize processes, ensuring you have an efficient and reliable process that balances productivity and cost.
We also have close working relationships with our colleagues at the Life Science Business within Merck, allowing us to shape new technologies that can contribute to your success.
Video: Setting up a global network of biodevelopment centers.
Our Martillac facility has been upgraded to a single-use platform, using our own products and technologies, and is now creating GMP batches for our clients.
In 2018, we added to our network by opening new biodevelopment centers in Boston, USA and Shanghai, China for process development and non-GMP production.
With all these facilities across the globe, we can support your vital work wherever it takes place.
About BioReliance® End-to-End SolutionsWe are an adaptable CDMO partner for start-ups and small biotechs needing to develop and commercialize biologics. We do this by balancing speed, risk and cost through custom solutions, by leveraging our bioprocessing technologies and process development expertise, and by allowing our clients to transfer their process and knowledge to their end point at any step of their drug development. |
Download brochure » |